Search | Médecins Sans Frontières Access Campaign

62 results found

Issue brief |

29 March 2016

The 3P Project - Accelerating Innovation and Access to Medicines for Tuberculosis

Tags Research and development tuberculosisdrug-resistant TB 3PCEWGLife Prizeresearch and development (R&D)

Technical brief |

22 January 2016

138th WHO EB - Briefing on R&D Blueprint- Agenda Item 9.1

Tags Research and development Ebola research and development (R&D) WHO Executive BoardWorld Health Organization

Nanyanyiso Baloi holds her treatment regimen for pre-XDR-TB, which includes delamanid and bedaquiline. Khayelitsha, Western Cape, South Africa..

Opinion article |

10 April 2015

TB Patients Take the Stage: Now for an R&D Model That Meets Their Needs

Tags Research and developmentTuberculosis tuberculosisdrug-resistant TB 3PLife Prize

Statement |

30 April 2014

MSF responds to US Trade 301 Watch List

Tags Intellectual property and trade HIV/AIDS antiretroviral medicines evergreeningfree trade agreementTrans-Pacific Partnership Agreement (TPP)TRIPS PEPFARPHARMACEUTICAL Companies India

Statement |

02 April 2014

Submission to the US Trade Representative Regarding the 2014 Special 301 Review Process

Tags Intellectual property and trade HIV/AIDS antiretroviral medicines free trade agreementTrans-Pacific Partnership Agreement (TPP)TRIPS PEPFAR India

Statement |

31 January 2014

MSF responds to news of pull out of neglected disease R&D by AstraZeneca

Tags Research and development malarianeglected diseasestuberculosis research and development (R&D) BayerPHARMACEUTICAL CompaniesAstraZeneca

Speech |

25 January 2013

MSF Intervention on Neglected Tropical Diseases at 132nd WHO Executive Board

Tags Intellectual property and tradeTropical & neglected diseases neglected diseasesvisceral leishmaniasis (kala azar) research and development (R&D) World Health Organization

Feature story |

19 December 2012

Looking Ahead to 2013 with MSF's Dr Manica Balasegaram

Tags HIV/AIDSIntellectual property and tradeResearch and developmentTropical & neglected diseasesTuberculosisVaccines HIV/AIDSneglected diseasestuberculosis vaccines research and development (R&D) Novartis Novartis Drop the Case Campaign

Video |

17 December 2012

Medicines Shouldn't be a Luxury

Medicines are essential for health and survival. But far too often, they’re priced like luxury items. We’re working to change that.

Tags HIV/AIDSIntellectual property and tradeResearch and developmentTropical & neglected diseasesTuberculosisVaccines drug-resistant TBHIV/AIDSneglected diseasestuberculosis research and development (R&D)

Video |

13 December 2012

Kala Azar: Still Waiting

Tags Intellectual property and tradeResearch and developmentTropical & neglected diseases neglected diseasesvisceral leishmaniasis (kala azar) research and development (R&D) Sudan

Press release |

12 December 2012

Millions of Patients Still Waiting for Medical “Breakthroughs” Against Neglected Diseases

Tags HIV/AIDSIntellectual property and tradeResearch and developmentTropical & neglected diseasesTuberculosisVaccines neglected diseasessleeping sicknessvisceral leishmaniasis (kala azar) research and development (R&D)

Video |

12 December 2012

Fatal Neglect: The Global Health Revolution's Forgotten Patients

Tags Research and developmentTropical & neglected diseases sleeping sicknessvisceral leishmaniasis (kala azar)neglected diseasesChagas disease research and development (R&D)

Video |

12 December 2012

Multidrug-Resistant Tuberculosis: No Promises

Tags Intellectual property and tradeResearch and developmentTuberculosis tuberculosisdrug-resistant TB research and development (R&D) Tajikistan

Events |

11 December 2012

Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations

Tags HIV/AIDSIntellectual property and tradeResearch and developmentTropical & neglected diseasesTuberculosisVaccines drug-resistant TBHIV/AIDSneglected diseasessleeping sicknesstuberculosisvisceral leishmaniasis (kala azar) vaccines research and development (R&D)

Press release |

03 December 2012

MSF response to the launch of the G-FINDER report

Tags Intellectual property and tradeResearch and developmentTropical & neglected diseases neglected diseasessleeping sicknessvisceral leishmaniasis (kala azar) research and development (R&D) World Health Organization

Research article |

30 August 2012

New research and development strategy for tuberculosis diagnostics urgently needed

Tags HIV/AIDSResearch and developmentTuberculosis tuberculosisco-infectionHIV/AIDS diagnostic testsresearch and development (R&D)

Press release |

11 June 2012

Neglected Tropical Diseases: New MSF Report Highlights How to Break the Cycle of Neglect

Tags Intellectual property and tradeResearch and developmentTropical & neglected diseases sleeping sicknessvisceral leishmaniasis (kala azar)neglected diseases research and development (R&D)

Report |

11 June 2012

Fighting Neglect

Tags Tropical & neglected diseases sleeping sicknessvisceral leishmaniasis (kala azar)neglected diseases research and development (R&D)

Video |

11 June 2012

NTDs: The Perfect Recipe for Disaster

Tags Research and developmentTropical & neglected diseases neglected diseasessleeping sicknessvisceral leishmaniasis (kala azar) research and development (R&D)

Research article |

29 March 2012

Access to medicines in resource-limited settings: the end of a golden decade?

Tags HIV/AIDSIntellectual property and tradeMalariaResearch and developmentTuberculosis tuberculosisHIV/AIDSmalaria Doha DeclarationTRIPS

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

The 3P Project - Accelerating Innovation and Access to Medicines for Tuberculosis

138th WHO EB - Briefing on R&D Blueprint- Agenda Item 9.1

TB Patients Take the Stage: Now for an R&D Model That Meets Their Needs

MSF responds to US Trade 301 Watch List

Submission to the US Trade Representative Regarding the 2014 Special 301 Review Process

MSF responds to news of pull out of neglected disease R&D by AstraZeneca

MSF Intervention on Neglected Tropical Diseases at 132nd WHO Executive Board

Looking Ahead to 2013 with MSF's Dr Manica Balasegaram

Medicines Shouldn't be a Luxury

Kala Azar: Still Waiting

Millions of Patients Still Waiting for Medical “Breakthroughs” Against Neglected Diseases

Fatal Neglect: The Global Health Revolution's Forgotten Patients

Multidrug-Resistant Tuberculosis: No Promises

Lives in the Balance: Delivering Medical Innovations for Neglected Patients and Populations

MSF response to the launch of the G-FINDER report

New research and development strategy for tuberculosis diagnostics urgently needed

Neglected Tropical Diseases: New MSF Report Highlights How to Break the Cycle of Neglect

Fighting Neglect

NTDs: The Perfect Recipe for Disaster

Access to medicines in resource-limited settings: the end of a golden decade?